• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Cyclerion Therapeutics, Inc.

    Regina Graul, Ph.D., Promoted to Chief Executive Officer
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Appoints Regina Graul, Ph.D., as President
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Announces Reverse Stock Split
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Tickers CYCN
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.